Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare, genetic disorder of urea cycle metabolism characterized by either a neonatal-onset with manifestations of lethargy, poor feeding, vomiting and tachypnea or, more commonly, presentations in infancy, childhood or adulthood with chronic neurocognitive deficits, acute encephalopathy and/or coagulation defects or other chronic liver dysfunction.
Features include always present findings: Hyperornithinemia, Homocitrullinuria, Hyperammonemia, and Global developmental delay and others; and common findings: Scanning speech, Dysmetria, Spastic gait, and Motor delay and others. 38 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 16 | Scanning speech, Acute encephalopathy, Clonus |
Digestive system | 4 | Decreased liver function, Acute hepatitis, Enlarged liver (hepatomegaly) |
Muscles | 3 | Cerebral cortical atrophy, Low muscle tone (hypotonia), Chorioretinal atrophy |
Growth and development | 1 | Failure to thrive |
Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is characterized by variable clinical presentation and age of onset ranging from the neonatal period to adulthood. Those with neonatal onset are normal for the first 24-48 hours, followed by onset of symptoms related to hyperammonemia (poor feeding, vomiting, lethargy, low temperature, rapid breathing). Those with later onset may present with chronic neurocognitive deficits and/or unexplained seizures, spasticity, acute encephalopathy secondary to hyperammonemic crisis, or chronic liver dysfunction. Neurologic findings and cognitive abilities can continue to deteriorate despite early metabolic control that prevents hyperammonemia.
Source: GeneReviews — "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome"
SLC25A15 function has not been fully characterized.
Ornithine translocase deficiency is caused by mutations in the SLC25A15 gene on chromosome 13.
The SLC25A15 genotype does not correlate with the clinical or biochemical phenotype of HHH syndrome .
Source: GeneReviews — "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome"
Suggestive Findings Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome should be suspected in symptomatic individuals with the following age-related clinical, laboratory, and neuroimaging findings. Clinical Findings Neonatal presentation (~8% of individuals). Manifestations of hyperammonemia usually begin 24-48 hours after the start of feeding and can include lethargy, somnolence, refusal to feed, vomiting, tachypnea with respiratory alkalosis, and/or seizures. Infantile, childhood, and adolescent/adult presentation (~92% of individuals) may exhibit any of the following: • Chronic neurocognitive deficits including developmental and speech delay, ataxia, spasticity, learning disabilities, cognitive deficits, and/or unexplained seizures • Acute encephalopathy secondary to hyperammonemic crisis, which can be precipitated by infection, fasting, or injury (or occur for no apparent reason) and can manifest as lethargy, decreased appetite, nausea, vomiting, increased respiratory rate, and seizures • Chronic liver dysfunction characterized by unexplained elevation of liver enzymes (AST and ALT) with or without mild coagulopathy and with or without mild hyperammonemia. • Mild encephalopathy manifesting as disorientation, irritability, and episodic confusion with mild hyperammonemia, which is difficult to detect as it may resolve spontaneously without treatment or quickly normalize with IV solutions that include glucose . Laboratory Findings Episodic or postprandial mild to moderate hyperammonemia. Plasma ammonia concentrations at the time of diagnosis are summarized in . Note that neonates have a higher median plasma ammonia level than older affected individuals. Note: (1) In HHH syndrome the degree of hyperammonemia is usually significantly less than in other urea cycle disorders such as OTC, ASS, or CPS-I deficiency (see Urea Cycle Disorders). (2) Once an affected individual is placed on a protein-restricted diet and treated with sodium phenylbutyrate , plasma ammonia concentrations return to normal. Table 1. Plasma Ammonia Concentrations Observed in HHH Syndrome by Age of Diagnosis Plasma Ammonia Concentration in mol/L by Age of Diagnosis1
Neonatal (birth – 1 mo) (n=6) | Infantile (1 mo – 1 yr) (n=5) | Childhood (1 yr – 12 yrs) (n=36) | Adolescence to Adulthood (12 yrs) (n=17) | Total (n=64) |
|---|---|---|---|---|
Median | 300 | 173 | 120 | 117 |
Mean | 560 | 577 | 160 | 119 |
SD | 507 | 965 | 121 | 69 |
Source: GeneReviews — "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome"
Most commonly, neonates with hyperammonemia and neonatal-onset HHH syndrome are initially suspected of having sepsis. See for a comprehensive algorithm for the differential diagnosis of neonatal hyperammonemia based on plasma and urine metabolites. Like other urea cycle disorders (UCDs), HHH syndrome should be included in the differential diagnosis of any individual with hyperammonemia, including women who experience hyperammonemia during or following pregnancy. The onset and severity of findings in HHH syndrome are more variable and less severe when compared to UCDs like ornithine transcarbamylase (OTC) deficiency or carbamyl phosphate synthase (CPS-I) deficiency (OMIM 237300).
Source: GeneReviews — "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome"
Genetic testing for SLC25A15 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for ornithine translocase deficiency has been reported in the published literature.
No approved treatments are currently available for ornithine translocase deficiency. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs of an individual diagnosed with the hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) Syndrome
System/Concern | Evaluation | Comment |
|---|---|---|
Constitutional | Measurement of HT, WT, HC | Always consider ethnic/geographic origin as it may influence baseline HT WT. |
Neurologic | Assess cerebellar motor function (gait postural ataxia, dysmetria, dysdiadochokinesis, tremor, dysarthria, nystagmus, saccades smooth pursuit) | Use standardized scale to establish baseline for ataxia (SARA, ICARS, or BARS)1 Refer to neuromuscular clinic (OT/PT/ rehabilitation specialist) |
Musculoskeletal | Assess for skeletal involvement related to spasticity. | — |
Speech | For those w/dysarthria: speech-language evaluation | Improving speech can secondary behavior problems contribute to dietary adherence. |
Feeding | For those w/recurrent vomiting or severe dysphagia: assess nutritional status, aspiration risk. |
Source: GeneReviews — "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome"
Avoid the following:
Excess dietary protein intake
Nonprescribed protein supplements such as those used to increase size of skeletal muscle during exercise regimens
Prolonged fasting during an illness or weight loss
Use of oral and intravenous steroids
Valproic acid, which induces and exacerbates hyperammonemia in urea cycle disorders
Exposure to communicable diseases
Source: GeneReviews — "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome"
1 trial found
All surveillance of individuals with HHH syndrome should be a combined effort of the general pediatrician or adult practitioner and a metabolic team (metabolic geneticist, metabolic dietician, and social worker). Table 7. Recommended Surveillance for Individuals with Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) syndrome
System/Concern | Evaluation | Frequency |
|---|---|---|
Constitutional | Measure HT, WT, HC. BMI should always be included. | From time of diagnosis until adolescence; During pre-school years: follow WT, HT HC in conjunction w/PCP even when not seen in metabolic clinic. Metabolic status |
eating | Parents should be alert to subtle behavior changes which may suggest plasma concentrations of glutamine ammonia. | Incl changes in eating habits, motor skills, behavior; In children age ≤3 yrs, especially in flu season or hot/humid weather |
Development | Evaluation by developmental pediatrician to assess manage emergence of behavior issues (ADD/ADHD) | Prior to starting kindergarten; evaluate as needed. Academic |
performance3 | Neurocognitive evaluation | 1x/yr if any academic regression or behavior changes occur Neurologic |
evaluation | A detailed evaluation by neurologist especially in children w/neonatal, infantile, early school-age onset to assess for slow, progressive neurologic involvement | Monitor 1x/yr even when metabolic control is optimal, especially in children age 12 yrs. Perform MRI/MRS in consultation w/neurologist. |
Source: GeneReviews — "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome"
Phenotype severity distribution: 6 always present features, 10 common features.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
15 publications have been identified in PubMed for ornithine translocase deficiency. Research spans Review / Meta-Analysis (43%), Case Report / Case Series (36%), and Diagnostic / Biomarker (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 6 | 43% |
Patient case studies | 5 | 36% |
Testing and diagnosis research | 2 | 14% |
Disease patterns and progression | 1 | 7% |
Huang XW (2026). [PMID: 41452423](https://pubmed.ncbi.nlm.nih.gov/41452423/). *World J Pediatr*. [Review / Meta-Analysis]
Das AM (2025). [PMID: 40285952](https://pubmed.ncbi.nlm.nih.gov/40285952/). *Metab Brain Dis*. [Review / Meta-Analysis]
Nauerz C (2025). [PMID: 40836422](https://pubmed.ncbi.nlm.nih.gov/40836422/). *Biol Chem*. [Review / Meta-Analysis]
Erdal R (2025). [PMID: 40710547](https://pubmed.ncbi.nlm.nih.gov/40710547/). *Metabolites*. [Review / Meta-Analysis]
Mohamed AS (2025). [PMID: 41189871](https://pubmed.ncbi.nlm.nih.gov/41189871/). *Cureus*. [Case Report / Case Series]
Ju H (2025). [PMID: 41126296](https://pubmed.ncbi.nlm.nih.gov/41126296/). *Orphanet J Rare Dis*. [Case Report / Case Series]
Cappuccio E (2025). [PMID: 39642098](https://pubmed.ncbi.nlm.nih.gov/39642098/). *FEBS J*. [Review / Meta-Analysis]
Richard E (2024). [PMID: 39449289](https://pubmed.ncbi.nlm.nih.gov/39449289/). *J Inherit Metab Dis*. [Review / Meta-Analysis]
Nguyen KN (2024). [PMID: 39597062](https://pubmed.ncbi.nlm.nih.gov/39597062/). *Medicina (Kaunas)*. [Epidemiology / Natural History]
Veldman A (2024). [PMID: 39846587](https://pubmed.ncbi.nlm.nih.gov/39846587/). *Int J Neonatal Screen*. [Diagnostic / Biomarker]
Data assembled from 9 of 12 sources · Last updated Sep 18, 2026, 10:52 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
111-1300 |
49-2300 |
25-532 |
18-250 |
Consider involving a gastroenterology/ nutrition/ feeding team. |
Psychiatric | Neuropsychiatric evaluation | In individuals age 12 mos: screen for problems incl sleep disturbances, ADHD, /or anxiety. |
Liver | Evaluate for evidence of hepatic dysfunction - biochemical profile US. | transaminases coagulopathy resolve after implementation of protein-restricted diet. Miscellaneous/ |
Other | Family support resources | Community or such as Parent to Parent Consultation w/clinical or metabolic geneticist, genetic counselor, metabolic dietician, /or social worker |
AI-curated news mentioning ornithine translocase deficiency
Updated Jul 31, 2026
In 1999, 18-year-old Jesse Gelsinger died in a clinical trial meant to test the safety of an adenovirus vector in support of a potential gene therapy treatment for ornithine transcarbamylase deficiency, a genetic liver disease. A recent tragedy in China reminds us of important lessons for managing drug trials of gene therapies And while fundamental research in support of gene therapies continued, it wasn’t until 2014 that the US ran another clinical trial on a gene therapy. In 2026, we must not let this latest incident set us back. The promise of gene therapy is far too great, and to realize that promise requires a bold leap forward that will protect patients and the science. At their best, gene therapies offer potential one-time, permanent cures for debilitating genetic disease. Gene therapies are not like any other drug. It’s true that death is a, thankfully, rare part of some drug trials. But gene therapy’s greatest advantage—its permanence—is also a great weakness in a clinical trial: you can’t stop once you’ve begun. If a patient has a negative reaction to a more typical drug, the overseeing clinician can stop a subsequent administration. Typical drug trials have also become routine. Institutional review boards generally know what to look for before approving a trial. And often the drugs being tested now are built on several generations of drugs tested before. Our knowledge and experience create a safety net. ... But gene therapy is a new business.
A study identifies two cryptic variants in the OTC gene responsible for ornithine transcarbamylase deficiency in unrelated Chinese male patients. This research enhances understanding of the genetic underpinnings of this rare metabolic disorder.
Ultragenyx reports positive 36-week data from its Phase 3 study of DTX301, an AAV8 gene therapy for ornithine transcarbamylase (OTC) deficiency. This therapy aims to address the unmet needs of over 10,000 patients affected by OTC deficiency, particularly those with late-onset forms of the disease.
PackGene Biotech is advancing AAV gene therapy for rare diseases, focusing on novel capsids for targeted delivery and dual-vector strategies for large genes. Ongoing trials are investigating therapies for glycogen storage diseases, urea cycle disorders like ornithine transcarbamylase deficiency, and phenylketonuria.